HEPATOPROTECTIVE MECHANISM OF SILYMARIN - NO EVIDENCE FOR INVOLVEMENT OF CYTOCHROME-P450 2E1

被引:60
|
作者
MIGUEZ, MP
ANUNDI, I
SAINZPARDO, LA
LINDROS, KO
机构
[1] ALKO LTD, BIOMED RES CTR, SF-00101 HELSINKI, FINLAND
[2] UNIV EXTREMADURA, FAC VET, PHARMACOL & TOXICOL UNIT, CACERES, SPAIN
关键词
ALCOHOL; FLAVONOID ANTIOXIDANT; HEPATOPROTECTIVE MECHANISM; LIVER CYTOCHROME P450 2E1; SILYMARIN;
D O I
10.1016/0009-2797(94)90006-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The involvement of the alcohol-inducible cytochrome P450 2E1 in the hepatoprotective mechanism of the plant flavonoid extract silymarin, and its main active component silybin, was investigated in isolated hepatocytes. Allyl alcohol toxicity, associated lipid peroxidation and GSH depletion was efficiently counteracted by silymarin (0.01-0.5 mM), and at higher concentrations by silybin. Cell damage by I-butyl hydroperoxide was also prevented by silymarin and silybin, but less efficiently. However, the covalent binding of the acetaminophen intermediate, formed via P450 2E1, was unaffected by addition of the flavonoids. Silybin did not influence microsomal 2E1-catalyzed demethylation of N-nitrosodimethylamine. Neither did demethylation of N-nitrosodimethylamine or aminopyrine by isolated microsomes affect the in vivo administration of silybin. Addition of silymarin or silybin to primary cultures of isolated hepatocytes did not prevent cell damage induced by exposure to the P450 2E1 substrate CCl4. In contrast, the mere presence of low concentrations (25-50 mu M) of these compounds was found to inhibit cell attachment to the matrix and eventually resulted in cell damage. We conclude that contrary to earlier reports we found no evidence for an interaction of silymarin or silybin with cytochrome P450 2E1. This suggests that the antioxidant and free radical scavenging properties may account for most of the therapeutic effect of these compounds. The untoward effect of silymarin on cultured cells may have consequences when considering long-term prescription of this therapeutic agent.
引用
收藏
页码:51 / 63
页数:13
相关论文
共 50 条
  • [21] RELATIONSHIP BETWEEN CYTOCHROME-P450 2E1 AND ACETONE CATABOLISM IN RATS AS STUDIED WITH DIALLYL SULFIDE AS AN INHIBITOR
    CHEN, LS
    LEE, MJ
    HONG, JY
    HUANG, WQ
    WANG, E
    YANG, CS
    BIOCHEMICAL PHARMACOLOGY, 1994, 48 (12) : 2199 - 2205
  • [22] MUTAGENESIS AT A HIGHLY CONSERVED PHENYLALANINE IN CYTOCHROME-P450 2E1 AFFECTS HEME INCORPORATION AND CATALYTIC ACTIVITY
    PORTER, TD
    BIOCHEMISTRY, 1994, 33 (19) : 5942 - 5946
  • [23] CLINICAL SEVOFLURANE METABOLISM AND DISPOSITION .2. THE ROLE OF CYTOCHROME-P450 2E1 IN FLUORIDE AND HEXAFLUOROISOPROPANOL FORMATION
    KHARASCH, ED
    ARMSTRONG, AS
    GUNN, K
    ARTRU, A
    COX, K
    KAROL, MD
    ANESTHESIOLOGY, 1995, 82 (06) : 1379 - 1388
  • [24] MODULATION OF EXPERIMENTAL ALCOHOL-INDUCED LIVER-DISEASE BY CYTOCHROME-P450 2E1 INHIBITORS
    MORIMOTO, M
    HAGBJORK, AL
    WAN, YJY
    FU, PC
    CLOT, P
    ALBANO, E
    INGELMANSUNDBERG, M
    FRENCH, SW
    HEPATOLOGY, 1995, 21 (06) : 1610 - 1617
  • [25] CATALYTIC PROPERTIES OF THE HUMAN CYTOCHROME-P450 2E1 PRODUCED BY CDNA EXPRESSION IN MAMMALIAN-CELLS
    PATTEN, CJ
    ISHIZAKI, H
    AOYAMA, T
    LEE, MJ
    NING, SM
    HUANG, W
    GONZALEZ, FJ
    YANG, CS
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1992, 299 (01) : 163 - 171
  • [26] Phenotyping of cytochrome P450 2E1 in vitro and in vivo
    Ernstgard, Lena
    Johanson, Gunnar
    Karlsson, Anne-Sophie
    Warholm, Margareta
    CURRENT DRUG METABOLISM, 2007, 8 (05) : 493 - 498
  • [27] Genetic polymorphism of human cytochrome P450 2E1
    Nedelcheva, V
    Persson, I
    IngelmanSundberg, M
    CYTOCHROME P450, PT B, 1996, 272 : 218 - 225
  • [28] Inactivation of cytochrome P450 2E1 by benzyl isothiocyanate
    Moreno, RL
    Kent, UM
    Hodge, K
    Hollenberg, PF
    CHEMICAL RESEARCH IN TOXICOLOGY, 1999, 12 (07) : 582 - 587
  • [29] Cytochrome P450 2E1 and its roles in disease
    Guengerich, F. Peter
    CHEMICO-BIOLOGICAL INTERACTIONS, 2020, 322
  • [30] Clinical isoflurane metabolism by cytochrome P450 2E1
    Kharasch, ED
    Hankins, DC
    Cox, K
    ANESTHESIOLOGY, 1999, 90 (03) : 766 - 771